Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo taps Mogrify for off-the-shelf CAR-Treg project","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery"},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Venture Management","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mogrify Extends Series A Financing to $46 Million USD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Mogrify

    Menu

    Mogrify

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Mogrify

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mogrify Extends Series A Financing to $46 Million USD

              Details:

              The financing will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.

              Lead Product(s): Undisclosed

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Astellas Venture Management

              Deal Size: $46.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing October 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mogrify

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss

              Details:

              As part of the collaboration, Astellas Gene Therapies, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus based genetic medicine and translational capabilities to complete experiments in pre-clinical models.

              Lead Product(s): AAV-Based Genetic Medicine

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Astellas Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mogrify

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sangamo taps Mogrify for off-the-shelf CAR-Treg project

              Details:

              Mogrify will discover and optimize cell conversion technology from iPSCs or ESCs to regulatory T cells. Sangamo will use Mogrify’s technology to create Tregs from iPSCs or ESCs.

              Lead Product(s): CAR-Treg cell therapy

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Sangamo Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement April 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY